Biomedical Innovation Expansion Act of 2019

Bill: 116-hr-4667
Sponsor: full_name: Rep. Sherrill, Mikie [D-NJ-11]
Introduced: 2019-10-11
Policy area: Health
Subjects: Cancer

Cell biology and embryology

Drug safety, medical device, and laboratory regulation

Government trust funds

Health programs administration and funding

Health promotion and preventive care

Medical research

Neurological disorders

Research administration and funding
Latest action: action_date: 2019-10-14
text: Referred to the Subcommittee on Health.

Summaries:
action_date: 2019-10-11
action_desc: Introduced in House
text: <p><b>Biomedical Innovation Expansion Act of 2019</b><br> <br> This bill expands and reauthorizes through FY2030 the National Institutes of Health innovation projects, which include the (1) All of Us Research Programs, (2) Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative, (3) Cancer Moonshot research, and (4) Regenerative Medicine Innovation Project. The bill also provides new funding for antimicrobial resistance research and for the research of rare diseases or conditions.</p>

tv_txt: I 116th CONGRESS 1st Session H. R. 4667 IN THE HOUSE OF REPRESENTATIVES October 11, 2019 Ms. Sherrill (for herself, Mr. Levin of California , and Ms. Spanberger ) introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To amend the 21st Century Cures Act to reauthorize funding for NIH innovation projects, and for other purposes.

1. Short title This Act may be cited as the Biomedical Innovation Expansion Act of 2019 . 2. Reauthorization of NIH innovation proj­ects (a) Transfers Section 1001(b)(2)(A) of the 21st Century Cures Act ( Public Law 114–255 ) is amended by striking clauses (v) through (x) and inserting the following: (v) For fiscal year 2021, $854,000,000. (vi) For fiscal year 2022, $1,051,000,000. (vii) For fiscal year 2023, $1,345,000,000. (viii) For fiscal year 2024, $1,271,000,000. (ix) For fiscal year 2025, $1,301,000,000. (x) For fiscal year 2026, $1,306,000,000. (xi) For fiscal year 2027, $1,336,000,000. (xii) For fiscal year 2028, $1,376,000,000. (xiii) For fiscal year 2029, $1,436,000,000. (xiv) For fiscal year 2030, $1,469,000,000. . (b) Authorization of appropriations Section 1001(b)(3)(A) of the 21st Century Cures Act ( Public Law 114–255 ) is amended by striking 2026 and inserting 2030 . (c) Offsetting future appropriations Section 1001(b)(3)(B) of the 21st Century Cures Act ( Public Law 114–255 ) is amended by striking 2026 and inserting 2030 . (d) NIH innovation projects Section 1001(b)(4) of the 21st Century Cures Act ( Public Law 114–255 ) is amended— (1) in the matter preceding subparagraph (A), by striking 2026 and inserting 2030 ; (2) in subparagraph (A)— (A) in the matter preceding clause (i), by striking $1,455,000,000 and inserting $4,413,000,000 ; and (B) by striking clauses (v) through (x) and inserting the following: (v) For fiscal year 2021, $209,000,000. (vi) For fiscal year 2022, $300,000,000. (vii) For fiscal year 2023, $419,000,000. (viii) For each fiscal years 2024 through 2030, $430,000,000. ; (3) in subparagraph (B)— (A) in the matter preceding clause (i), by striking $1,511,000,000 and inserting $4,428,000,000 ; and (B) by striking clauses (v) through (x) and inserting the following: (v) For fiscal year 2021, $250,000,000. (vi) For fiscal year 2022, $302,000,000. (vii) For fiscal year 2023, $450,000,000. (viii) For each of fiscal years 2024, 2025, and 2026, $400,000,000. (ix) For fiscal year 2027, $425,000,000. (x) For fiscal years 2028, $450,000,000. (xi) For each of fiscal years 2029 and 2030, $500,000,000. ; (4) in subparagraph (C)— (A) in the matter preceding clause (i), by striking $1,800,000,000 and inserting $3,312,000,000 ; and (B) by amending clause (vii) to read as follows: (vii) For each of fiscal years 2023 through 2030, $216,000,000. ; (5) in subparagraph (D)— (A) in the matter preceding clause (i), by striking $30,000,000 and inserting $250,000,000 ; and (B) by striking clause (iv) and inserting the following: (iv) For each of fiscal years 2021, 2022, and 2023, $50,000,000. (v) For each of fiscal years 2024 through 2030, $10,000,000. ; and (6) by adding at the end the following: (E) To support research related to combating antimicrobial resistance and antibiotic resistant bacteria, not to exceed a total of $1,635,000,000, as follows: (i) For fiscal year 2021, $100,000,000. (ii) For each of fiscal years 2022 through 2024, $150,000,000. (iii) For each of fiscal years 2025 through 2027, $175,000,000. (iv) For each of fiscal years 2028 and 2029, $180,000,000. (v) For fiscal year 2030, $200,000,000. (F) To support research and research activities related to rare diseases or conditions, not to exceed a total of $758,000,000, as follows: (i) For fiscal year 2021, $50,000,000. (ii) For fiscal year 2022, $55,000,000. (iii) For fiscal year 2023, $60,000,000. (iv) For fiscal year 2024, $65,000,000. (v) For fiscal year 2025, $70,000,000. (vi) For fiscal year 2026, $75,000,000. (vii) For fiscal year 2027, $80,000,000. (viii) For fiscal year 2028, $90,000,000. (ix) For fiscal year 2029, $100,000,000. (x) For fiscal year 2030, $113,000,000. . (e) Workplan Section 1001(c)(1)(A) of the 21st Century Cures Act ( Public Law 114–255 ) is amended by striking 2026 and inserting 2030 . (f) Recommendations Section 1001(c)(1)(C)(i) of the 21st Century Cures Act ( Public Law 114–255 ) is amended by striking 2026 and inserting 2030 . (g) Annual reports Section 1001(c)(2)(A) of the 21st Century Cures Act ( Public Law 114–255 ) is amended by striking 2027 and inserting 2030 . (h) Sunset Section 1001(e) of the 21st Century Cures Act ( Public Law 114–255 ) is amended by striking September 30, 2026 and inserting September 30, 2030 .